December 11, 2024 -- InvestorsHub NewsWire -- via PESG Research -- The field of precision oncology has witnessed groundbreaking advancements in recent years, and Silexion Therapeutics (NASDAQ: SLXN) has emerged as a pioneering force. By leveraging RNA interference (RNAi) technology, Silexion is tackling KRAS-driven cancers, an area long considered one of oncology’s most formidable challenges. With recent milestones, a robust pipeline, and favorable market dynamics, the company appears poised to transform cancer treatment and position itself as a potential target in a space where billion-dollar acquisitions have become the norm. Yesterday, the company announced the appintment of Prof. Amnon Peled, a globally renwoed cancer theapeutics expert to its board of directors, further strengthening its position.,

 

Addressing the KRAS Challenge

KRAS mutations are the most common oncogenic drivers in human cancers, implicated in over 90% of pancreatic cancers and a significant proportion of lung, colorectal, and other cancers. Despite decades of research, KRAS mutations have proven difficult to target effectively, earning the moniker “undruggable.” Traditional approaches have focused on inhibiting KRAS at the protein level, with limited success.

Silexion’s innovative approach centers on silencing KRAS mutations at the genetic level. The company’s proprietary Local Drug EluteR (LODER™) platform delivers siRNA directly to tumor sites, bypassing the dense tumor microenvironment that often impedes systemic therapies. The platform’s ability to silence oncogenes locally offers a dual benefit: enhanced efficacy and reduced systemic side effects.

 

Promising Clinical Data

Silexion’s first-generation product, LODER, has shown remarkable results in Phase 2 trials for non-resectable locally advanced pancreatic cancer (LAPC). When combined with standard-of-care chemotherapy, LODER improved overall survival by 9.3 months compared to chemotherapy alone. The trial also demonstrated a 56% objective response rate (ORR), with a striking 67% resectability improvement in tumors previously deemed inoperable. This data underscores LODER’s potential to shift the treatment paradigm for one of the most aggressive and fatal cancers.

The company is now advancing its second-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations (pan-G12x and G13D). Recent preclinical studies have further validated SIL-204’s potential. In mouse xenograft models, a single administration of SIL-204’s extended-release microparticle formulation significantly reduced tumor size and induced high levels of tumor necrosis. This marks a significant improvement over earlier formulations and positions SIL-204 as a frontrunner in RNAi-based oncology therapies.

 

Expanding Beyond Pancreatic Cancer

While Silexion’s initial focus is on pancreatic cancer, its RNAi technology holds promise for other KRAS-driven cancers, including colorectal and lung cancers. The company plans to initiate preclinical studies for SIL-204 in colorectal cancer models, a logical next step given the high prevalence of KRAS mutations in this cancer type. If successful, this expansion could substantially broaden Silexion’s addressable market and further solidify its position as a leader in precision oncology.

 

Recent Strategic Developments

Silexion has taken significant steps to strengthen its position, including a 1-for-9 reverse share split to maintain its Nasdaq listing and enhance its market positioning. The split, effective November 29, 2024, aims to stabilize the company’s stock and create a stronger foundation for future equity financings.

Additionally, Silexion’s recent appointment of Prof. Amnon Peled, a globally recognized authority in cancer therapeutics, to its Board of Directors marks a strategic move to bolster its scientific and strategic expertise. Prof. Peled’s decades-long track record of advancing novel cancer therapies from discovery to FDA approval aligns seamlessly with Silexion’s mission and could accelerate its pipeline’s progress.

 

Market Dynamics and M&A Potential

The precision oncology market is experiencing explosive growth, driven by innovations like Silexion’s RNAi platform. The global precision medicine market is projected to grow from $102 billion in 2024 to $470 billion by 2034, with a compound annual growth rate (CAGR) of 16.5%. Within this market, the KRAS inhibitors segment alone is expected to grow at a 36% CAGR, reaching $10 billion by 2032.

This robust growth has fueled a surge in mergers and acquisitions (M&A). Pfizer’s $43 billion acquisition of Seagen in 2023 and AbbVie’s $10.1 billion purchase of Immunogen highlight Big Pharma’s appetite for innovative oncology assets. Silexion’s unique approach to targeting KRAS mutations positions it as a potentially attractive acquisition target, especially as large pharmaceutical companies seek to fill gaps in their oncology pipelines.

 

The Road Ahead

Silexion’s advancements in RNAi technology, coupled with its focus on one of the most challenging cancer targets, make it a compelling player in the precision oncology space. The company’s LODER platform has already demonstrated transformative potential in pancreatic cancer, and the upcoming clinical development of SIL-204 could further validate its innovative approach.

While challenges remain—drug development is inherently risky, and RNAi therapies are still a relatively new frontier—Silexion’s progress to date and its strategic initiatives provide a strong foundation for growth. As the company continues to push the boundaries of oncology innovation, it stands at the intersection of high unmet medical need and significant market opportunity.

 

 

****

Important disclaimers and disclosures: This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The pharma, biotech, precision medicine, and other industries and or markets mentioned are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This report is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. PESG Research is a commercial digital brand operated for IR purposes compensated by  the issuer aforementioned to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest.

 

SOURCE: PESG Research

Mainz BioMed NV (NASDAQ:MYNZ)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Mainz BioMed NV
Mainz BioMed NV (NASDAQ:MYNZ)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Mainz BioMed NV